Genetic Mutation Analysis Market Growth Outlook Reveals A CAGR Of 11.5% And A Market Value Of $11.47 Billion By 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Genetic Mutation Analysis Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for genetic mutation analysis has experienced substantial growth in recent years, expanding from $6.65 billion in 2025 to $7.43 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.7%. This historical expansion has been driven by several factors, including restricted availability of advanced sequencing methods, heightened public awareness regarding genetic conditions, intensified research efforts in oncology and hereditary disorders, the widespread implementation of PCR and microarray technologies, and the initial development of bioinformatics tools.
The market for genetic mutation analysis is projected to experience substantial expansion in the coming years, with its value anticipated to reach $11.47 billion by 2030, reflecting a compound annual growth rate (CAGR) of 11.5%. This forecast period growth is driven by progress in CRISPR and next-generation sequencing platforms, a broader focus on pharmacogenomics research, heightened investment in genetic testing infrastructure, the incorporation of artificial intelligence into data interpretation tools, and an increase in partnerships between research institutes and biotechnology firms. Key trends shaping the forecast period encompass the widespread adoption of next-generation sequencing and CRISPR technologies, a growing demand for personalized medicine and targeted therapies, the extension of genetic testing services within clinical diagnostics, the integration of bioinformatics and data analysis platforms, and intensified research on rare genetic disorders and pharmacogenomics.
Download A Free Sample Report For Comprehensive Market Insights:
Genetic Mutation Analysis Market Growth Momentum: Which Factors Are Influencing Demand?
Increased occurrences of genetic conditions are anticipated to drive forward the expansion of the genetic mutation analysis market. Genetic disorders arise from irregularities or alterations within an individual’s DNA, which can either be inherited or develop without a specific cause. Contributing to this growing prevalence is advanced parental age, which heightens the likelihood of genetic mutations occurring during reproduction, thereby raising the probability that offspring will develop such conditions. By examining changes in genes that may indicate or lead to genetic disorders, mutation analysis facilitates early detection, focused therapies, and better-informed choices regarding reproduction and lifestyle. An illustration comes from October 2024, when the Cystic Fibrosis Trust—a UK organization dedicated to supporting those affected by cystic fibrosis—reported 11,148 registered patients with this condition in 2022, a figure that climbed to 11,318 by 2023, marking a 1.5% annual increase in registrations. Hence, the growing prevalence of these genetic conditions is fueling the expansion of the genetic mutation analysis market.
Genetic Mutation Analysis Market Segments: Where Are The Largest Growth Opportunities?
The genetic mutation analysis market covered in this report is segmented –
1) By Component: Hardware, Software, Services
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, Sanger Sequencing, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
3) By Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Genetic Disorders, Pharmacogenomics
4) By End User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories
Subsegments:
1) By Hardware: Sequencers, Polymerase Chain Reaction (PCR) Machines, Microarray Instruments, Electrophoresis Systems, Imaging Systems
2) By Software: Data Analysis Software, Sequence Alignment Tools, Variant Calling Software, Genome Annotation Software, Visualization Tools
3) By Services: Genetic Testing Services, Data Interpretation Services, Bioinformatics Services, Sample Preparation Services, Clinical Reporting Services
Genetic Mutation Analysis Market Trends Reshaping Industry Growth
Leading players within the genetic mutation analysis market are placing significant emphasis on creating cutting-edge solutions, including tissue-based next-generation sequencing (NGS) assays, intended to improve accuracy in detecting actionable genetic changes and inform customized treatment approaches. These tissue-based NGS assays represent sophisticated diagnostic tools capable of examining DNA or RNA extracted from tissue specimens to uncover genetic mutations, modifications, or biological markers linked to illnesses like cancer. In June 2024, for example, Guardant Health Inc., a U.S.-based oncology firm, introduced the Guardant360 TissueNext assay, which broadens the spectrum of genes identifiable in a tumor tissue specimen to 498. These identified genes, functioning as cancer markers, empower oncologists to pinpoint targeted therapies or treatment regimens that prove most effective for individuals dealing with advanced cancer. Alongside the expanded gene panel, Guardant has refined the test’s operational procedures to accelerate result delivery. The newly available Guardant360 TissueNext assay will be reimbursed for Medicare fee-for-service patients diagnosed with advanced solid tumor cancers as an independent service, relying on coverage guidelines issued by Palmetto GBA, a Medicare administrative contractor overseeing the Molecular Diagnostics Services program (MolDX), under the previously established local coverage determination.
Genetic Mutation Analysis Market Major Participants And Competitive Dynamics
Major companies operating in the genetic mutation analysis market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., GenScript Biotech Corporation, Takara Bio Inc., 10x Genomics Inc., Oxford Nanopore Technologies Plc, Genomic Health Inc., Color Genomics Inc., Blueprint Medicines Corporation, GENEWIZ Inc., Pacific Biosciences of California Inc., Standard BioTools Inc., Personalis Inc., LGC Biosearch Technologies LLC, BGI Genomics Co. Ltd.
Access The Complete Genetic Mutation Analysis Market Report:
Genetic Mutation Analysis Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the genetic mutation analysis market in 2025. The regions covered in the genetic mutation analysis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
